Multi-layer Hydrogel Capsules for Cell Encapsulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current alginate microcapsules for cell encapsulation face challenges such as inadequate immune protection, fibrotic reactions, and incomplete cell coverage, leading to rejection and failure of transplanted islets, particularly due to biocompatibility issues and fibrotic overgrowth.
Innovation Solution
Development of biocompatible capsules with specific physical characteristics, including a diameter of 1-10 mm, spheroid shape, surface pores between 0-10 μm, neutral or hydrophilic surfaces, and absence of flat sides or sharp angles, made from materials like hydrogels, ceramics, and polymers, which reduce fibrotic reactions and enhance biocompatibility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If alginate microcapsules are used for cell encapsulation, then cells are protected from immune system, but fibrotic reactions and foreign body responses occur leading to capsule rejection
Solution Approach 1:
The patent applies parameter changes by modifying the physical characteristics of the capsule surface, specifically controlling surface curvature to be between 0.1 and 2.0, surface area to be between 10 and 1000 mm², and pore size to be between 0.1 and 10 μm. These parameter adjustments optimize the balance between immune protection and fibrotic response reduction.
Solution Approach 2:
The patent uses composite materials by combining hydrogel core material with polymeric shell materials, creating a multi-layer structure that integrates the protective properties of hydrogel with the fibrotic-response-modulating properties of engineered polymeric surfaces.
2Reliability
If capsule surface area is increased to improve cell coverage, then immune protection is enhanced, but fibrotic overgrowth increases
Solution Approach 1:
The patent optimizes the capsule surface area parameter to fall within the specific range of 10 to 1000 mm², which has been determined to provide sufficient immune protection while minimizing fibrotic overgrowth. This precise parameter control resolves the contradiction between protection and harmful response.
Solution Approach 2:
The patent applies spheroidality by controlling the surface curvature to be between 0.1 and 2.0, creating a smoothly curved surface that reduces fibrotic response while maintaining adequate surface area for immune protection. The curved geometry prevents sharp angles that would trigger fibrotic overgrowth.
3Reliability
If capsule size is reduced to improve diffusion of nutrients and oxygen, then cell viability is improved, but fibrotic reactions increase
Solution Approach 1:
The patent resolves this contradiction by independently optimizing multiple parameters: capsule diameter (1-10 mm), surface area (10-1000 mm²), and pore size (0.1-10 μm). These coordinated parameter changes allow adequate diffusion while maintaining surface characteristics that minimize fibrotic response.
Solution Approach 2:
The patent applies porous materials by incorporating pores of controlled size (0.1 to 10 μm) into the capsule structure, which enables diffusion of nutrients and oxygen while the porous configuration with optimized surface area reduces fibrotic overgrowth compared to solid capsules of the same size.
4Object-affected harmful factors
If capsule surface is made hydrophobic to reduce protein adsorption, then fibrotic reaction is reduced, but cell coverage and immune protection are compromised
Solution Approach 1:
The patent changes the surface hydrophobicity parameter to create a hydrophilic surface with controlled curvature (0.1-2.0) and surface area (10-1000 mm²), which simultaneously achieves reduced fibrotic response and maintained immune protection through optimized geometric parameters.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The capsules exhibit reduced fibrotic reactions and improved biocompatibility, allowing for long-term viability and functionality of transplanted cells, with reduced immune response and prolonged therapeutic efficacy, such as sustained insulin secretion for treating diabetes.
Implementation Method 1
capsules are designed to allow facile diffusion of oxygen and nutrients to the encapsulated cells
Implementation Method 2
Alginate hydrogel microcapsules have been broadly investigated for their utility with pancreatic islets to treat Type I diabetes... formed through ionic crosslinking... The alginate droplet is gelled upon contact with a solution of divalent ions, such as Ca2+ or Ba2+
Implementation Method 3
capsules are designed to allow facile diffusion of oxygen and nutrients to the encapsulated cells
Data Source
AI summary
Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.